Cytokine networks in Pemphigus vulgaris: An integrated viewpoint

Autoimmunity

Volumn 45, Issue 6, 2012, Pages 427-439

  Giordano, Cerrene N ^a   Sinha, Animesh A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Autoimmunity; Cytokines; Pemphigus vulgaris; T lymphocytes

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; TOCILIZUMAB; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA; USTEKINUMAB;

ANTIBODY PRODUCTION; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; NONHUMAN; PEMPHIGUS VULGARIS; PHENOTYPE; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH2 CELL;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; CYTOKINES; DESMOGLEIN 3; HUMANS; PEMPHIGUS; TH17 CELLS; TH2 CELLS;

EID: 84864964981     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2012.697593     Document Type: Review

References (88)

1. D'Auria L, Bonifati C, Mussi A, D'Agosto G, De Simone C, Giacalone B, Ferraro C, Ameglio F. Cytokines in the sera ofpatients with pemphigus vulgaris: Interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw 1997;8:383-387.
2. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: Population based cohort study. Br Med J 2008;337:a180.
3. Kitajima Y, Aoyama Y. A perspective of pemphigus from bedside and laboratory-bench. Clin Rev Allergy Immunol 2007;33:57-66.
4. Rizzo C, Fotino M, Zhang Y, Chow S, Spizuoco A, Sinha AA.Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with ctive disease. Clin Exp Dermatol 2005;30: 535-540.
5. Yokoyama T, Amagai M. Immune dysregulation of pemphigus in humans and mice. J Dermatol. 2010;37:205-213.
6. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991;67:869-877.
7. Hertl M. Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Int Arch Allergy Immunol 2000;122: 91-100.
8. Mahoney MG,Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999;103:461-468.
9. Ludwig RJ, Schmidt E. Cytokines in autoimmune bullous skindiseases. Epiphenomena or contribution to pathogenesis? G Ital Dermatol Venereol 2009;144:339-349.
10. Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994;94:59-67.
11. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982;306: 1189-1196.
12. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992;90:919-926.
13. Buchanan R, Popowych Y, Dagenais C, Arsic N, Mutwiri GK, Potter AA, Babiuk LA, Griebel PJ, Wilson HL. Interferongamma and B-cell Activating Factor (BAFF) promote bovine B cell activation independent of TLR9 and T-cell signaling.Veter immunol immunopathol [Research Support, Non-U.S. Gov't] 2012;145:453-463.
14. Mackay F, Schneider P. Cracking the BAFF code. Nature Rev Immunol [Research Support, Non-U.S. Gov't Review] 2009; 9:491-502.
15. Satyam A, Khandpur S, Sharma VK, Sharma A. Involvement of T(H)1/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris. Immunol Invest 2009;38: 498-509.
16. Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T. Use of autoantigen-knockout mice in developingan active autoimmune disease model for pemphigus. J Clin Invest 2000;105:625-631.
17. Aoki-Ota M, Tsunoda K, Ota T, Iwasaki T, Koyasu S, Amagai M, Nishikawa T. A mouse model of pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice. Br J Dermatol 2004;151: 346-354.
18. Nishifuji K, Amagai M, Kuwana M, Iwasaki T, Nishikawa T. Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: Requirement of T cell collaboration for autoantibody production. J Invest Dermatol 2000;114:88-94.
19. Takahashi H, Amagai M, Nishikawa T, Fujii Y, Kawakami Y, Kuwana M. Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine pemphigus vulgaris. J Immunol 2008;181:1526-1535.
20. Scharf SJ, Friedmann A, Brautbar C, Szafer F, Steinman L, Horn G, Gyllensten U, Erlich HA. HLA class II allelic variation and susceptibility to pemphigus vulgaris. Proc Natl Acad Sci USA 1988;85:3504-3508.
21. Sinha AA, Brautbar C, Szafer F, Friedmann A, Tzfoni E, Todd JA, Steinman L, McDevitt HO. A newly characterized HLA DQ beta allele associated with pemphigus vulgaris. Science 1988;239:1026-1029.
22. Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, McDermott M, Sinha AA, Timmerman L, Steinman L, et al. A molecular basis for MHC class II-associatedautoimmunity. Science 1988;240:1003-1009.
23. Veldman C, Stauber A, Wassmuth R, Uter W, Schuler G, Hertl M. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris(PV) and healthy carriers of PV-associated HLA class II alleles.J Immunol 2003;170:635-642.
24. Hertl M, Amagai M, Sundaram H, Stanley J, Ishii K, Katz SI. Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. J Invest Dermatol 1998;110:62-66.
25. Kricheli D, David M, Frusic-Zlotkin M, Goldsmith D, RabinovM, Sulkes J, Milner Y. The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol 2000;143:337-342.
26. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: A model for autoimmunity. Proc Natl Acad Sci USA 1995;92:5239-5243.
27. Hernandez C, Amagai M, Chan LS. Pemphigus foliaceus: Preferential binding of IgG1 and C3 at the upper epidermis. Br J Dermatol 1997;136:249-252.
28. Tremeau-Martinage C, Oksman F, Bazex J. [Immunoglobulin G subclass distribution of anti-intercellular substance antibodies in pemphigus]. Ann Dermatol Venereol 1995;122: 409-411.
29. Spaeth S, Riechers R, Borradori L, Zillikens D, Budinger L, Hertl M. IgG, IgA and IgE autoantibodies against theectodomain of desmoglein 3 in active pemphigus vulgaris. Br J Dermatol 2001;144:1183-1188.
30. Ayatollahi M, Joubeh S, Mortazavi H, Jefferis R, Ghaderi A. IgG4 as the predominant autoantibody in sera from patients with active state of pemphigus vulgaris. J Eur Acad Dermatol Venereol 2004;18:241-242.
31. David M, Katzenelson V, Hazaz B, Ben-Chetrit A, Sandbank M. Determination of IgG subclasses in patients with pemphigus with active disease and in remission. Arch Dermatol 1989;125:787-790.
32. Hacker MK, Janson M, Fairley JA, Lin MS. Isotypes and antigenic profiles of pemphigus foliaceus and pemphigus vulgaris autoantibodies. Clin Immunol 2002;105:64-74.
33. Jones CC, Hamilton RG, Jordon RE. Subclass distribution of human IgG autoantibodies in pemphigus. J Clin Immunol 1988;8:43-49.
34. Kim YH, Geoghegan WD, Jordon RE. Pemphigus immunoglobulin G subclass autoantibodies: Studies of reactivity with cultured human keratinocytes. J Lab Clin Med 1990;115: 324-331.
35. Yamada H, Hashimoto T, Nishikawa T. IgG subclasses of intercellular and basement membrane zone antibodies: The relationship to the capability of complement fixation. J Invest Dermatol 1989;92:585-587.
36. Futei Y, Amagai M, Ishii K, Kuroda-Kinoshita K, Ohya K, Nishikawa T. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J Dermatol Sci. 2001;26: 55-61.
37. Armitage RJ, Macduff BM, Spriggs MK, Fanslow WC.Human B cell proliferation and Ig secretion induced by recombinant CD40 ligand are modulated by soluble cytokines. J Immunol 1993;150:3671-3680.
38. Romagnani S. Human TH1 and TH2 subsets: Regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 1992;98:279-285.
39. Lin MS, Swartz SJ, Lopez A, Ding X, Fernandez-Vina MA, Stastny P, Fairley JA, Diaz LA. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J Clin Invest 1997;99:31-40.
40. Veldman C, Hohne A, Dieckmann D, Schuler G, Hertl M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol 2004;172:6468-6475.
41. Wucherpfennig KW, Yu B, Bhol K, Monos DS, Argyris E, Karr RW, Ahmed AR, Strominger JL. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: Charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA 1995;92: 11935-11939.
42. Huilgol SC, Black MM. Management of the immunobullous disorders. II. Pemphigus. Clin Exp Dermatol 1995;20: 283-293.
43. Hashimoto T. Recent advances in the study of the pathophysiology of pemphigus. Arch Dermatol Res 2003; 295 Suppl 1:S2-S11.
44. Keskin DB, Stern JN, Fridkis-Hareli M, Razzaque Ahmed A. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy. ytokine 2008;41:315-321.
45. Bhol KC, Rojas AI, Khan IU, Ahmed AR. Presence of interleukin 10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid. Cytokine 2000;12: 1076-1083.
46. Narbutt J, Lukamowicz J, Bogaczewicz J, Sysa-Jedrzejowska A, Torzecka JD, Lesiak A. Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris. Mediators Inflamm 2008;2008:875394.
47. Rico MJ, Benning C,Weingart ES, Streilein RD, Hall RP, 3rd.Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris. Br J Dermatol 1999;140:1079-1086.
48. Nawijn MC, Dingjan GM, Ferreira R, Lambrecht BN, Karis A, Grosveld F, Savelkoul H, Hendriks RW. Enforced expression of GATA-3 in transgenic mice inhibits Th1 differentiation and induces the formation of a T1/ST2- expressing Th2-committed T cell compartment in vivo. J Immunol 2001;167:724-732.
49. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997;89:587-596.
50. Williams TM, Fox KR, Kant JA. Interleukin-2: Basic biology and therapeutic use. Hematol Pathol 1991;5:45-55.
51. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 006;441:235-238.
52. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485-517.
53. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8: 345-350.
54. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006;441:231-234.
55. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007;13:139-145.
56. Arakawa M, Dainichi T, Yasumoto S, Hashimoto T. Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus. J Dermatol Sci 2009;53:228-231.
57. Sugiyama H, Matsue H, Nagasaka A, Nakamura Y, Tsukamoto K, Shibagaki N, Kawamura T, Kitamura R, Ando N, Shimada S. CD4 CD25high regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris. Dermatology 2007;214:210-220.
58. Alecu M, Alecu S, Coman G, Galatescu E, Ursaciuc C. ICAM-1, ELAM-1, TNF-alpha and IL-6 in serum and blister liquid of pemphigus vulgaris patients. Roum Arch Microbiol Immunol 1999;58:121-130.
59. Lopez-Robles E, Avalos-Diaz E, Vega-Memije E, Hojyo-Tomoka T, Villalobos R, Fraire S, Domiguez-Soto L, Herrera-Esparza R. TNFalpha and IL-6 are mediators in the blistering process of pemphigus. Int J Dermatol 2001;40: 185-188.
60. Grando SA, Glukhenky BT, Drannik GN, Epshtein EV, Kostromin AP, Korostash TA. Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 1989;125:925-930.
61. Feliciani C, Toto P, Amerio P, Pour SM, Coscione G, Shivji G, Wang B, Sauder DN. In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: Interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 2000;114:71-77.
62. Bhol KC, Desai A, Kumari S, Colon JE, Ahmed AR. Pemphigus vulgaris: The role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production. Clin Immuno 2001; 100:172-180.
63. Feliciani C, Toto P, Amerio P. In vitro C3 mRNA expression in Pemphigus vulgaris: Complement activation is increased by IL-1alpha and TNF-alpha. J Cutan Med Surg 1999;3: 140-144.
64. Feliciani C, Toto P, Wang B, Sauder DN, Amerio P, Tulli A. Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis. Exp Dermatol 2003;12:466-471.
65. Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, Bystryn JC, Cianchini G, Diaz L, Fivenson D, Hall R, Harman KE, Hashimoto T, Hertl M, Hunzelmann N, Iranzo P, Joly P, Jonkman MF, Kitajima Y, Korman NJ, Martin LK, Mimouni D, Pandya AG, Payne AS, Rubenstein D, Shimizu H, Sinha AA, Sirois D, Zillikens D, Werth VP. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008;58:1043-1046.
66. Arend WP, Joslin FG, Massoni RJ. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J Immunol 1985;134: 3868-3875.
67. Dinarello CA, Thompson RC. Blocking IL-1: Interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12:404-410.
68. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007;448: 484-487.
69. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, Dong C. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007;448:480-483.
70. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8:967-974.
71. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, Cua DJ. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007;8:1390-1397.
72. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99-146.
73. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46:3143-3150.
74. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-1110.
75. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997;349:521-524.
76. Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 2004;74:245-247.
77. Lin MH, Hsu CK, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 2005;141:680-682.
78. Gubinelli E, Bergamo F, Didona B, Annessi G, Atzori F, RaskovicD. Pemphigus foliaceus treated with etanercept. J Am Acad Dermatol 2006;55:1107-1108.
79. Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severepemphigus vulgaris. Br J Dermatol 2005;153:222-223.
80. Jacobi A, Shuler G, Hertl M. Rapid control of therapyrefractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005; 153:448-449.
81. Howell SM, Bessinger GT, Altman CE, Belnap CM. Rapid response of IgA pemphigus of the subcorneal pustular Dermatosis subtype to treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol 2005;53: 541-543.
82. Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009;11:81-89.
83. Fiorito S, Magrini L. Autoimmune features in atherosclerotic ischemic cardiomyopathy. Allerg Immunol (Paris) 1992;24: 336-341.
84. Ayroldi E, Bastianelli A, Cannarile L, Petrillo MG,DelfinoDV, Fierabracci A. A pathogenetic approach to autoimmune skin disease therapy: Psoriasis and biological drugs, unresolved issues, and future directions. Curr Pharm Des 2011;17(29): 3176-3190.
85. Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM. Preclinical efficacy and safety of pascolizumab (SB 240683): A humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002;130:93-100.
86. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebocontrolled trial. Am J Respir Crit Care Med 1999;160: 1816-1823.
87. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149:926-937.
88. Namazi MR, Fallahzadeh MK, Shaghelani H, Kamali-Sarvestani E. Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris. Int J Dermatol 2010;49:146-148.